Toward the development of bivalent ligand probes of cannabinoid CB1 and Orexin OX1 receptor heterodimers

ACS Medicinal Chemistry Letters

Volumn 5, Issue 6, 2014, Pages 634-638

  Perrey, David A ^a   Gilmour, Brian P ^a   Thomas, Brian F ^a   Zhang, Yanan ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

bivalent ligands; Cannabinoid; heterodimer; orexin

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ALMOREXANT; CANNABINOID 1 RECEPTOR AGONIST; HETERODIMER; LIGAND; PHENYLACETIC ACID DERIVATIVE; RIMONABANT;

ALKYLATION; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84902515287     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4004759     Document Type: Article

References (37)

1. Milligan, G. G protein-coupled receptor dimerization: function and ligand pharmacology Mol. Pharmacol. 2004, 66, 1-7
2. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors Nat. Rev. Neurosci. 2001, 2, 274-286
3. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function Br. J. Pharmacol. 2009, 158, 5-14
4. Hiller, C.; Kuhhorn, J.; Gmeiner, P.; Class, A. G-protein-coupled receptor (GPCR) dimers and bivalent ligands J. Med. Chem. 2013, 56, 6542-6559
5. George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug. Discovery 2002, 1, 808-820
6. Minneman, K. P. Heterodimerization and surface localization of G protein coupled receptors Biochem. Pharmacol. 2007, 73, 1043-1050
7. Milligan, G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery Drug. Discovery Today 2006, 11, 541-549
8. Kearn, C. S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 2005, 67, 1697-1704
9. Mackie, K. Cannabinoid receptor homo- and heterodimerization Life Sci. 2005, 77, 1667-1673
10. Wager-Miller, J.; Westenbroek, R.; Mackie, K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example Chem. Phys. Lipids 2002, 121, 83-89
11. Schoffelmeer, A. N.; Hogenboom, F.; Wardeh, G.; De Vries, T. J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core Neuropharmacology 2006, 51, 773-781
12. Cvejic, S.; Devi, L. A. Dimerization of the delta opioid receptor: implication for a role in receptor internalization J. Biol. Chem. 1997, 272, 26959-26964
13. Filizola, M.; Weinstein, H. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers Biopolymers 2002, 66, 317-325
14. Garzon, J.; Juarros, J. L.; Castro, M. A.; Sanchez-Blazquez, P. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain Mol. Pharmacol. 1995, 47, 738-744
15. Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 2004, 47, 2969-2972
16. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H. H.; Pintar, J. E.; Devi, L. A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5135-5139
17. Kearn, C. S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 2005, 67, 1697-1704
18. Ng, G. Y.; O'Dowd, B. F.; Lee, S. P.; Chung, H. T.; Brann, M. R.; Seeman, P.; George, S. R. Dopamine D2 receptor dimers and receptor-blocking peptides Biochem. Biophys. Res. Commun. 1996, 227, 200-204
19. Guo, W.; Shi, L.; Javitch, J. A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer J. Biol. Chem. 2003, 278, 4385-4388
20. Herrick-Davis, K. Functional significance of serotonin receptor dimerization Exp. Brain Res. 2013, 230, 375-386
21. Ellis, J.; Pediani, J. D.; Canals, M.; Milasta, S.; Milligan, G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function J. Biol. Chem. 2006, 281, 38812-38824
22. Hilairet, S.; Bouaboula, M.; Carriere, D.; Le Fur, G.; Casellas, P. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716 J. Biol. Chem. 2003, 278, 23731-23737
23. Hervieu, G. J.; Cluderay, J. E.; Harrison, D. C.; Roberts, J. C.; Leslie, R. A. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord Neuroscience 2001, 103, 777-797
24. Cota, D.; Marsicano, G.; Tschop, M.; Grubler, Y.; Flachskamm, C.; Schubert, M.; Auer, D.; Yassouridis, A.; Thone-Reineke, C.; Ortmann, S.; Tomassoni, F.; Cervino, C.; Nisoli, E.; Linthorst, A. C.; Pasquali, R.; Lutz, B.; Stalla, G. K.; Pagotto, U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J. Clin. Invest. 2003, 112, 423-431
25. Crespo, I.; Gomez de Heras, R.; Rodriguez de Fonseca, F.; Navarro, M. Pretreatment with subeffective doses of rimonabant attenuates orexigenic actions of orexin A-hypocretin 1 Neuropharmacology 2008, 54, 219-225
26. Gupta, A.; Mulder, J.; Gomes, I.; Rozenfeld, R.; Bushlin, I.; Ong, E.; Lim, M.; Maillet, E.; Junek, M.; Cahill, C. M.; Harkany, T.; Devi, L. A. Increased abundance of opioid receptor heteromers after chronic morphine administration Sci. Signaling 2010, 3, ra54
27. Albizu, L.; Cottet, M.; Kralikova, M.; Stoev, S.; Seyer, R.; Brabet, I.; Roux, T.; Bazin, H.; Bourrier, E.; Lamarque, L.; Breton, C.; Rives, M. L.; Newman, A.; Javitch, J.; Trinquet, E.; Manning, M.; Pin, J. P.; Mouillac, B.; Durroux, T. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues Nat. Chem. Biol. 2010, 6, 587-594
28. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
29. Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 2001, 44, 2259-2269
30. Zheng, Y.; Akgun, E.; Harikumar, K. G.; Hopson, J.; Powers, M. D.; Lunzer, M. M.; Miller, L. J.; Portoghese, P. S. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands J. Med. Chem. 2009, 52, 247-258
31. Zhang, Y.; Gilliam, A.; Maitra, R.; Damaj, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 2010, 53, 7048-7060
32. Koberstein, R.; Aissaoui, H.; Bur, D.; Clozel, M.; Fischli, W.; Jenck, F.; Mueller, C.; Nayler, O.; Sifferlen, T.; Treiber, A.; Weller, T. Tetrahydroisoquinolines as orexin receptor antagonists: strategies for lead optimization by solution-phase chemistry Chimia 2003, 57, 270-275
33. Perrey, D. A.; German, N. A.; Gilmour, B. P.; Li, J. X.; Harris, D. L.; Thomas, B. F.; Zhang, Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor J. Med. Chem. 2013, 56, 6901-6916
34. Perrey, D. A.; Gilmour, B. P.; Runyon, S. P.; Thomas, B. F.; Zhang, Y. Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 2980-2985
35. Malherbe, P.; Borroni, E.; Pinard, E.; Wettstein, J. G.; Knoflach, F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists Mol. Pharmacol. 2009, 76, 618-631
36. Tanaka, T.; Nomura, W.; Narumi, T.; Masuda, A.; Tamamura, H. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells J. Am. Chem. Soc. 2010, 132, 15899-15901
37. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 2011, 6, 963-974